Here's Why Akero Therapeutics Is Surging Today
Shares of Akero Therapeutics (NASDAQ: AKRO), a clinical-stage biopharmaceutical company, are on the move after the company's lead candidate succeeded in a controlled clinical trial. Investors impressed with the results have pushed the stock 22% higher as of 1:36 p.m. EDT on Tuesday.
Non-alcoholic steatohepatitis (NASH) is a potentially fatal condition caused by inflammation of a fatty liver. Around a quarter of adults in the U.S. have livers with dangerously high fat levels and around a fifth of this group progress to NASH. Since there aren't any available treatment options, Akero's lead candidate could generate blockbuster sales if it continues to succeed.
Image source: Getty Images.
Source Fool.com
